Common metastatic sites after crizotinib resistance

Crizotinib is a targeted anti-cancer drug. Common metastasis sites after crizotinib resistance include central system metastasis, bone metastasis, liver metastasis, etc. The resistance time to crizotinib varies from person to person. Clinical data shows that the resistance time is generally 8—14 months. When patients take crizotinib, they should be reviewed regularly. If resistance occurs, the treatment plan should be changed promptly according to the doctor's recommendations to reduce the progression of the disease.

Crizotinib is used to treat adult patients with metastatic non-small cell lung cancer caused by defects in the anaplastic lymphoma kinase (ALK) gene or the ROS1 gene. Also used to treat children 1 year of age and older and young adults with systemic anaplastic large cell lymphoma (ALCL) of ALK+. In 20227month, FDA approved crizotinib for the treatment of adults and 1(ALK)positive inflammatory myofibroblastic tumor(IMT) in children aged an>years and older who cannot be surgically removed, have recurred, or have failed other treatments. Crizotinib blocks the activity of proteins in tumors with genetic changes, an effect that helps the cancer grow and spread. Crizotinib is an oral prescription drug produced by Pfizer, usually taking one capsule twice a day. When taking crizotinib, strictly follow your doctor's instructions. Crizotinib bioavailability: 43% (Average absolute bioavailability), average accumulation ratio: 4.8, plasma peak time: 4-6 hours, crizotinib reached steady state on day 15. Both Bangladesh and Laos pharmaceutical factories produce it. The retail price of Laos pharmaceutical factory is about 2 more than 2 per box, and the retail price of Bangladeshi pharmaceutical factory is about 2,000 to 3,000. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.

xa0